Navigation Links
Keryx Biopharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Date:10/19/2010

te), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: lfischer@keryx.com
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... MEETING, Pa. , Sept. 22, 2014 /PRNewswire/ ... announced today it has initiated a phase I ... trial will evaluate the safety, tolerability, and immunogenicity ... 6 (HPV-6), which causes most aerodigestive cancers. ... nose, throat, vocal cords, and parts of the ...
(Date:9/22/2014)... SAN DIEGO , Sept. 22, 2014 Arena ... the company is scheduled to present a corporate overview ... conference on Friday, September 26, 2014, at 11:30 a.m. ... Broadway Hotel in New York City ... presentation will be available under the investor relations section ...
(Date:9/22/2014)... Sept. 22, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... has been appointed President and Chief Executive Officer, effective ... has stepped down from his executive and Board roles ... through the first quarter of 2016.  ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5
(Date:9/22/2014)... Angeles, CA (PRWEB) September 22, 2014 ... life insurance industry is now easier using the Quotes ... who are trying to local universal life insurance pricing ... The adult coverage plans that are easily viewed when ... that underwrite specific lengths of coverage. The plan data ...
(Date:9/22/2014)... Manhattan residents who suffer with hip ... hip , which could be bursitis now have a ... now offered at New York Dynamic Neuromuscular Rehabilitation Center. ... occurs when the trochanteric bursa becomes irritated or inflamed. ... between the iliotibial band and the greater trochanter. Most ...
(Date:9/22/2014)... seems futuristic, if not impossible. But with a ... researchers at University of California, San Diego School ... an entire, functional eye a reality. , "A ... for vision restoration," said Jeffrey Goldberg, MD, PhD, ... at University of Pittsburg Medical Center and Boston ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 This Flash ... on stakeholder management needs for the Prostate Cancer market. ... Experts on stakeholder strategies for any launching Prostate Cancer ... of differentiation within an increasingly crowded market , ... The impact of identifying community-based thought leaders and stakeholders ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 The ... the nation’s leading nonprofit authority on the use ... information exchange, announced findings from its recent industry ... Plan Identifier (HPID) within electronic transactions adopted under ... WEDI conducted the survey from August 20 to ...
Breaking Medicine News(10 mins):Health News:Universal Life Insurance Prices for Adults Added to National Insurer Portal Online 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3
... aiding joint inflammations in conditions like // arthritis. ... of the immune cells to secrete chemicals that will ... to arthritis. The enzyme cathepsin G attracts accumulation of ... tissue and cartilage in joints leading to the inflammatory ...
... a common water pollutant called arsenic may not be the ... a gene called CYT19 in people, particularly in children, that ... arsenic. ,Arsenic exposure had long been associated with health ... problems, and neurological disorders. It can enter the body through ...
... could run using a pollution free energy source.// ... working towards this solution to look at making hydrogen fuel ... hydrogen would reacts with oxygen to produce water and energy. ... would be pollution free. A similar mechanism is already followed ...
... had lead to inability to curbing of inflammatory cells// ... likewise. Researchers from Oregon Health & Science University have ... the low immune problem that leads to progress of ... disease of the central nervous system. There is no ...
... Prostate cancer is the commonest cancer effecting men. Benefits ... watermelon, papaya and pink grapefruit( most lycopene in processed ... known for sometime in preventing the aging process ... It is now being looked at for preventing and ...
... People suffering from diabetes type 1 or type 2 ... tract infections and skin infections. ,Some other ... kidney damage, nerve damage, eye problems that can lead ... a major risk factor for incidence of diabetes of ...
Cached Medicine News:Health News:Pollution Free Hydrogen based fuel for Energy 2Health News:Pollution Free Hydrogen based fuel for Energy 3
Designed to meet the requirements of reagent grade water for routine analysis....
... L/min of Type I ultrapure water, , ... Plus System is designed to provide the ... pretreated by reverse osmosis, distillation or deionization. ... quality which exceeds Type I ASTM/CAP/NCCLS specifications.,The ...
... Basic Laboratory Needs, Synergy systems produce ultrapure water ... 1 to 1.2 L/min to meet the basic ... incorporates a dual-wavelength UV lamp (185 nm and ... of organic contaminants (< 5 ppb TOC when ...
... Compact System Produces Type I Water Directly from ... designed for scientists who need 5 to 15 ... not have easy access to acceptable quality pretreated ... 0.6 L/min of ultrapure (Type I) water on ...
Medicine Products: